Metastatic Breast Cancer Clinical Trials 2023

What are the top hospitals conducting metastatic breast cancer research?

When it comes to cutting-edge clinical trials for metastatic breast cancer, several renowned hospitals across the United States are leading the charge. In Saint Louis, Washington University School of Medicine is at the forefront with nine ongoing trials focused specifically on this aggressive form of breast cancer. Since recording their first trial in 2008, they have conducted a total of 15 studies dedicated to metastatic breast cancer. Meanwhile, Memorial Sloan Kettering Cancer Center in New York has been tackling this challenging condition since 2003, currently running eight active trials and having completed an impressive 64 past trials.

In Boston's medical landscape, two prominent institutions are also making significant contributions. Dana Farber Cancer Institute boasts seven ongoing clinical trials for metastatic breast cancer and a commendable track record of conducting 26 previous studies since initiating their first trial in 2007. Another institution within the city - Dana-Farber Cancer Institute - shares a similar name but maintains its own distinct accomplishments. With seven active trials and a history encompassing 34 past investigations dating back to their pioneering study in1999.

Massachusetts General Hospital joins these esteemed hospitals with six current clinical tests focusing on metastatic breast cancer while having accomplished thirty-six prior successful research initiatives from as early as back in yearsof2003. These remarkable efforts by top institutions emphasize the urgency placed upon understanding and treating metastatic breast cancer—a condition where the disease spreads beyond the initial site to other parts of the body—proving that through relentless commitment to research and innovation we come ever closer towards finding effective treatments or potentially even cures for this devastating illness that affects so many lives worldwide

Which are the best cities for metastatic breast cancer clinical trials?

When it comes to metastatic breast cancer clinical trials, several cities stand out as leaders in research and development. New York City has 35 active trials focusing on promising treatments like Abemaciclib, Sacituzumab Govitecan-hziy, and Giredestrant. Boston also stands strong with 34 ongoing studies exploring innovative approaches such as Abemaciclib, PF-07265807, and ABT-888. Honolulu shines in the field with 32 active trials investigating therapies like Palbociclib and Serum Tumor Marker directed disease monitoring. Houston follows closely behind with 29 trials studying Simvastatin 80mg, Giredestrant, nab-sirolimus, among others. Finally, Nashville dedicates its efforts to advancing care through 24 active trials centered around treatments like Abemaciclib, 9-ING-41,and ARV-471. These cities offer individuals battling metastatic breast cancer. New York City has 35 active trials focusing on promising treatments like Abemaciclib, Sacituzumab Govitecan-hziy, and Giredestrant. Boston also stands strong with 34 ongoing studies exploring innovative approaches such as Abemaciclib, PF-07265807, and ABT-888. Honolulu shines in the field with 32 active trials investigating therapies like Palbociclib and Serum Tumor Marker directed disease monitoring. Houston follows closely behind with 29 trials studying Simvastatin 80mg, Giredestrant, nab-sirolimus, among others. Finally, Nashville dedicates its efforts to advancing care through 24 active trials centered around treatments like Abemaciclib, 9-ING-41,and ARV-471. These cities offer individuals battling metastatic breast cancer access to cutting-edge clinical trials that hold promise for improved outcomes and better quality of life.

Which are the top treatments for metastatic breast cancer being explored in clinical trials?

Exciting advancements are being made in the field of metastatic breast cancer research, with several top treatments showing promise in clinical trials. Leading the pack is abemaciclib, currently undergoing exploration in five active trials for metastatic breast cancer. With its first listing dating back to 2014, it has garnered a respectable tally of 12 all-time trials dedicated to addressing this challenging disease. Trastuzumab follows closely behind, participating in three ongoing trials and boasting an impressive record of 19 all-time clinical studies since its introduction in 2006. Also making waves are talazoparib and trastuzumab deruxtecan—relatively newer additions that show great potential with three active trials each. These groundbreaking treatments offer hope for improved outcomes for individuals battling metastatic breast cancer.

What are the most recent clinical trials for metastatic breast cancer?

Exciting advancements in clinical trials for metastatic breast cancer offer hope and potential progress in the treatment of this challenging disease. One such trial focuses on elacestrant, a Phase 2 study that aims to evaluate its efficacy specifically for metastatic breast cancer patients. Additionally, a Phase 3 trial explores the combination of Inavolisib and Fulvestrant as a potential treatment option. Another promising approach involves combining ARV-471 with Abemaciclib, with both Phase 1 and Phase 2 trials investigating its effectiveness against metastatic breast cancer. Furthermore, ongoing research includes a Phase 1b cohort examining LOXO-435 monotherapy dose expansion and evaluating the impact of injections at varying doses. With these recent clinical trials paving the way forward, there is renewed optimism for improved outcomes in individuals facing metastatic breast cancer.

What metastatic breast cancer clinical trials were recently completed?

In recent years, several clinical trials have contributed to the advancement of treatments for metastatic breast cancer. Mirati Therapeutics Inc.'s MRTX849 trial concluded in August 2021, while I-Mab Biopharma Co. Ltd.'s TJ210001 trial ended in December 2020. In October and August of that same year, Merck Sharp & Dohme Corp. and Blue Earth Diagnostics completed their respective trials involving Pembrolizumab and 18F fluciclovine. These studies highlight ongoing efforts to find effective therapeutic options for patients facing this challenging condition, encouraging greater hope within the medical community and among those affected by metastatic breast cancer.